Skip to contentI
Inhibitor Therapeutics, Inc.
I
INTIInhibitor Therapeutics, Inc. Q2 2022 · 10-Q
Revenue$0.00$0.00— vs Q2 2021 Net Income-$77.57K-$77.57KN/M vs Q2 2021 EPS Diluted$0.00$0.00— vs Q2 2021 Operating Income-$70,804N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inhibitor Therapeutics, Inc. · CIK 1042418 · Engraved from SEC EDGAR
derived
ended Jun 30, 2022 · filed Aug 12, 2022 · 43 d after period end